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The  -adrenergic  blockers  and  antagonists  of the  renin-angiotensin  system  (RAS)  are  among  the  drugs
that  present  better results  in  the  control  of  cardio-metabolic  diseases.  The  aim  of  the  present  study  was
to  evaluate  the  effect  of  the association  of the  -blocker,  atenolol,  and  an  oral  formulation  of  Ang-(1–7)
on  lipid  metabolism  in spontaneously  hypertensive  rats  (SHR).  The  main  results  showed  that  SHR  treated
with oral  formulation  of  Ang-(1–7)  in  combination  to  atenolol  have  an improvement  of lipid  metabolism
with  a  reduction  of total  plasma  cholesterol,  improvement  of  oral  fat load  tolerance  and  an  increase  ineywords:
ngiotensin-(1–7)
as  receptor
tenolol
yslipidemia
HR
the lipolytic  response  stimulated  by the  -adrenergic  agonist,  isoproterenol,  without  modiﬁcation  of
resting  glucose  or insulin  sensitivity  in  adipocytes.  In conclusion,  we  showed  that  administration  of an
Ang-(1–7)  oral  formulation  in  association  with  a -blocker  induces  beneﬁcial  effects  on  dyslipidemia
treatment  associated  with  hypertension.
©  2013 Elsevier  Inc.  Open access under the Elsevier OA license.
enin-angiotensin system
. Introduction
Dyslipidemia is well recognized as one of the most pernicious
etabolic disorders, consisting in an important risk factor of car-
iovascular disease, the most prevalent worldwide [5,11]. Studies
ave shown a potential role for antihypertensive drugs on lipid
egulation [15]. -Adrenergic blockers and antagonists of the renin-
ngiotensin system (RAS) are among the drugs that present better
esults in the control of metabolic syndrome and dyslipidemia
4,15,25,27,29].
Recent studies point out for a role of ACE2/Angiotensin-
1–7)/Mas axis as an important counterregulatory arm of the RAS,
pposing several angiotensin (Ang) II actions in obesity [17,20,21].
ransgenic animals that present a life time increase in plasma Ang-
1–7) showed an improved lipid and glucose metabolism indicating
n important metabolic effect for Ang-(1–7) [20]. On the other
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ttp://dx.doi.org/10.1016/j.peptides.2013.03.009
Open access under the Elsevier OA license.hand, mice that lack the Ang-(1–7) receptor, Mas  [21], present a
metabolic-like syndrome [21].
-Blockers were also shown to present direct action on
metabolic tissues such as muscle, liver and adipose tissue
[10,18,26], inhibiting hormone-sensitive lipase activity in the
early weeks of treatment and modulating cholesterol biosynthesis
and/or catabolism [26]. In this context, the aim of the present study
was to evaluate the effect of the association of a -blocker, atenolol,
and an oral formulation of Ang-(1–7) [12] on lipid metabolism in
spontaneously hypertensive rats (SHR).
2. Materials and methods
2.1. Animals
Experiments were performed in male SHR (20 ± 2 weeks old)
obtained from the animal facilities Biological Science Institute
(CEBIO, UFMG, Belo Horizonte, MG,  Brazil) kept in 12 h light/dark
cycle room.
2.2. TreatmentFour group of animals received orogastric gavage (1 mL/kg,
daily) for 14 weeks of: (a) Ang-(1–7)/hydroxypropyl--
cyclodextrin [CD-Ang-(1–7), 30 g/kg/day of the peptide; n = 8];
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Fig. 1. Body weight (g; A) before and after treatment, fasting glucose levels (mg/dL; B) in the blood of animals treated for 8 weeks with: empty HP--CD (CD; n = 16); or
CD-Ang-(1–7) (n = 8); or atenolol (AT; n = 8); or CD-Ang-(1–7) associated with atenolol (CD-Ang-(1–7) + AT; n = 9). Triglycerides (mg/dL; C) and total cholesterol (mg/dL; D) in
the  serum of animals treated for 14 weeks with: CD-Ang-(1–7) (n = 7); or atenolol (AT; n = 8); or CD-Ang-(1–7) associated with atenolol (CD-Ang-(1–7) + AT; n = 8); or HP--CD
( s); #p
t
(
C
h
p
o
w
p
2
t
B
o
r
(
2
a
d
4
t
N
0
a
f
G
(
iCD;  n = 8). *p < 0.05 in comparison to before (Student’s t-test for paired observation
est).
b) -blocker (atenolol, 3 mg/kg/day; n = 8); (c) the association of
D-Ang-(1–7) and atenolol (n = 9) at same doses; and (d) vehicle,
ydroxypropyl--cyclodextrin (CD, 50 g/kg/day; n = 9). The
roportion of Ang-(1–7) and hydroxypropyl--cyclodextrin in the
ral formulation was 43% and 57%, respectively. Blood pressure
as measured in a group of animals by telemetry for 8 weeks, as
reviously described [3].
.3. Lipid proﬁle
After 14 weeks of treatment, total serum cholesterol and
riglycerides were measured by enzymatic method (Kit KATAL
iotecnológica Ind. Com. Ltd., Brazil) in fasted animals. In addition,
ral fat tolerance was evaluated by the changes in serum triglyce-
ides 60, 120, and 210 min  after oral administration of a fat load
10 mL/kg), as described by Mori et al. [14].
.4. Lipolysis
Lipolysis was measured by the rate of glycerol released from
dipocytes. To isolate adipocytes, the fat pads of epididymus were
igested with collagenase at 37 ◦C in a shaking water bath for
5 min. Next, cells were ﬁltered through nylon mesh and washed
hree times with a HEPES buffer (pH 7.4) containing: 137 mM
aCl, 5 mM KCl, 4.2 mM  NaHCO3, 1.3 mM CaCl2, 0.5 mM MgCl2,
.5 mM MgSO4, 0.5 mM KH2PO4, 20 mM HEPES and 1% BSA. After
 period of incubation, an aliquot of the infranatant was removed
or enzymatic determination of glycerol released into the medium.
lycerol levels were measured before and after isoproterenol
0.1 mol/L) or isoproterenol followed by insulin (12.5 ng/mL)
ncubation. < 0.05 in comparison to control-CD (one-way ANOVA followed by Newman–Keuls
2.5. Fasting glucose
At eighth week of treatment, fasting glucose was  evaluated in
tail blood sample using an Accu-Check glucometer (Roche Diagnos-
tics, Indianapolis, IN).
2.6. Glucose uptake
Glucose uptake was also measured in isolated adipocytes from
epididymal fat tissue. The isolated adipocytes were incubated for
45 min  at 37 ◦C in the presence or absence of insulin (50 ng/mL).
The uptake of 2-deoxy-[3H]glucose (2DOG) was used to determine
the insulin sensitivity in glucose uptake, as described by Green [7].
The assay was initiated by the addition of 2DOG (0.2 Ci/tube) for
3 min. Next, cells were separated by centrifugation through silicone
oil and cell-associated radioactivity was  determined by scintillation
counting. Nonspeciﬁc association of 2DOG was determined by per-
forming parallel incubations in the presence of 15 mmol/l phloretin,
and this value was subtracted from glucose transport activity in
each condition.
2.7. Lipoprotein lipase (LPL) activity
Epididymal fat pads were homogenized in buffer Tris–HCl (pH
8.3) containing detergents. LPL activity was measured using a [9,10-
3H]triolein containing substrate with lecithin [16] and 24 h fasted
rat plasma as a source of apo CII. The reaction was stopped with
a mixture of extraction [1], and the released 3H-free fatty acids
(FFAs) were quantiﬁed by liquid scintillation. The enzyme activity
was expressed as nanomoles of FFA released per minute.
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Fig. 2. Triglycerides in the serum (mg/dL; A) before and 60, 120 and 210 mim  after oral administration of fat; Serum glycerol (mg/dL; B) at baseline level of lipolysis (basal),
on  lipolysis stimulated by isoproterenol (ISO) and lipolysis after isoproterenol combined with insulin (ISO + insulin); glucose uptake measured by the 2-deoxy-[3H]glucose
(2-DOG,  nmol/3 min; C) uptake before (basal) and after insulin stimulation in isolated adipocytes from epididymal fat pads; Lipoprotein lipase activity (LPL, mmol [3H]-fatty
acid  released/min; D) in isolated adipocytes of epididymal fat pads of animals treated for 14 weeks with: HP--CD (CD; n = 6–9); CD-Ang-(1–7) (n = 7–8); or atenolol (AT;
n  = 6–8); or CD-Ang-(1–7) associated with atenolol (CD-Ang-(1–7) + AT; n = 5–8). §p < 0.05 in comparison to CD-Ang-(1–7) alone or CD-Ang-(1–7) associated to atenolol
(Two-way ANOVA followed by Bonferroni); *p < 0.05 in comparison basal (Student’s t-test for paired observation); †p < 0.05 in comparison to atenolol alone (one-way ANOVA
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.8. Statistical analysis
Data were presented as mean ± SE. Differences between before
nd after were assessed by Student t test for paired observations.
ifferences among groups were analyzed by one-way ANOVA fol-
owed by Newman–Keuls post hoc or two-way ANOVA followed
y Bonferroni post hoc. Statistical analysis was  performed using
he GraphPad Prism Software (version 5.0).
. Results
At the beginning of treatment, animals presented similar body
eight (averaged of all animals = 322 ± 5 g, n = 40; Fig. 1A). After
4 weeks of oral treatment, animals of all groups had signiﬁcantly
ncreased body weight and the values obtained were not differ-
nt among the groups (averaged of all animals = 391 ± 5 g, n = 40;
ig. 1A). In addition, only animals treated with the association of
ng-(1–7) and atenolol presented a small but signiﬁcant decrease
n systolic arterial pressure (161 ± 1 mmHg  vs 169 ± 1 mmHg,
efore treatment; n = 5; Paired Student’s t-test; data not shown).
 decrease in heart rate was observed in animals treated
ith atenolol alone (286 ± 1 beats/min vs 301 ± 1 beats/min,
efore; n = 5) or associated to Ang-(1–7) (278 ± 1 beats/min vs
93 ± 1 beats/min, before; n = 5).As shown in Fig. 1B, on the eighth week of treatment there
as no change in fasted glycemia in any of the groups. Although
tenolol alone had a trend to increase glucose levels, values were
ot statistically different.In order to evaluate lipid proﬁle, at the end of the 14 weeks of
treatment, total serum cholesterol, glycerol and triglycerides were
measured. As shown in Fig. 1C, CD-Ang-(1–7) or atenolol alone did
not alter serum triglycerides. However, animals that received the
association of CD-Ang-(1–7) and atenolol presented a ∼60% lower
values of total serum cholesterol (13 ± 3 mg/dL; Fig. 1D)  than con-
trol animals that received CD alone, vehicle (38 ± 5 mg/dL; Fig. 1D).
After oral administration of fat load, a hypertriglyceridemia
was observed in control (vehicle; 92 ± 33 mg/dL vs 34 ± 3 mg/dL,
before; Fig. 2A) or animals treated with atenolol, with a peak at
210 min  (115 ± 17 mg/dL vs 52 ± 6 mg/dL, before; Fig. 2A). This
alteration was not observed in the other groups: CD-Ang-(1–7)
alone (52 ± 10 mg/dL vs 35 ± 6 mg/dL, before; Fig. 2A) or in CD-Ang-
(1–7) associated with atenolol (48 ± 8 mg/dL 38 ± 4 mg/dL, before;
Fig. 2A).
Lipolysis was measured by the release of glycerol at baseline and
after isoproterenol stimulation or insulin inhibition. As expected,
isoproterenol increased glycerol release in all groups (Fig. 2B).
Although the basal lipolysis was  similar in all treatments, after
isoproterenol stimulation, the association of CD-Ang-(1–7) and
atenolol induced a greater lipolysis (120 ± 14 mg/dL; Fig. 2B) as
compared to atenolol alone (82 ± 7 mg/dL; Fig. 2B). Interestingly,
the sensitivity of insulin was not changed by any treatment (Fig. 2C).
Further, the sensitivity of insulin on glucose uptake was measured
in adipocytes by radioactivity into the cells, since 2DOG can be
transported but not oxidized. We  have observed that all treatments
did not change glucose uptake or the insulin sensitivity (Fig. 2C).
Lipoprotein lipase (LPL) is an enzyme that hydrolyzes triglyce-
rides components of lipoproteins providing free fatty acids (FFAs)
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nd monoacylglycerol for being used by tissues. The release 3H-
FAs was quantiﬁed by liquid scintillation as an estimative of LPL
ctivity. As shown in Fig. 2D, the LPL activity was not different in
ll groups studied.
. Discussion
The present study showed, for the ﬁrst time, the metabolic
ffect of an oral treatment with Ang-(1–7) associated with the -
locker-atenolol. It was observed that CD-Ang-(1–7) in association
ith atenolol reduced the total cholesterol, improved the oral fat
oad tolerance and increased the lipolitic response stimulated by
soproterenol without modiﬁcation of resting glucose or insulin
ensitivity in adipocytes of SHR.
Recent studies have shown that an increased activation of
CE2/Ang-1–7/Mas arm of the RAS produces important improve-
ent on lipid and glucose metabolism [2,8,13,19]. Increased circu-
ating Ang-(1–7) in transgenic rats decreases plasma triglyceride
nd cholesterol improving insulin sensitivity [20]. Corroborating
hese data it was shown that Mas  receptor deﬁcient mice present
ncreased body fat associated to insulin resistance and increased
lasma triglycerides and cholesterol levels [21]. A recent study
howed that oral treatment with Ang-(1–7) was able to improve
etabolism and decreases pro-inﬂammatory proﬁle in adipose
issue [22]. Our present data further extend these ﬁndings by show-
ng that oral treatment with Ang-(1–7) associated with atenolol
educes total cholesterol, improves fat load tolerance and increases
he lipolitic response in SHR. The reduced postprandial lipemia
nduced by Ang-(1–7) treatment may  contribute somehow to pre-
ent the development of atherosclerosis. This effect is relevant
ince the rise in triglyceride-rich lipoproteins after eating is asso-
iated with the occurrence of coronary artery disease [9]. It is
mportant to emphasize that the present study is the ﬁrst to evalu-
te lipid metabolic response in an arterial hypertension rat model
reated with an oral formulation of Ang-(1–7).
Several clinical trials evaluated the lipid metabolic effects of
tenolol and -blockers in patients with hypertension and dyslipid-
mia [6,24,28]. In general, it was observed improvement in glucose
nd lipid metabolism that may  reduce the risk of coronary artery
isease in high-risk patients with hypertension [6]. On the other
and, several studies did not show an important effect of atenolol
n lipid proﬁle [6,24], pointing out for the necessity of combined
herapies for treating patients with dyslipidemia. Our study shows
hat the association of Ang-(1–7) with atenolol maybe an impor-
ant alternative therapy for treating hypertension associated with
yslipidemia.
Although intriguing, the decrease in cholesterol levels in the
resence of unchanged fasting glucose and triglycerides concentra-
ions in animals treated with Ang-(1–7) associated with atenolol,
ould be consequence of the increased uptake of HDL-cholesterol
articles from the plasma to the liver by increasing the reverse
holesterol transport [23]. The vasodilator effects of Ang-(1–7) [19]
ould increase the access of the lipids particles to HDL-cholesterol
eceptors stimulating the clearance of HDL particles by the liver.
n the present study a small decrease in systolic blood pressure
as observed only in animals treated with atenolol associated to
ng-(1–7), suggesting that the vasodilatatory actions of Ang-(1–7)
otentiated the effects of the -blocker on peripheral resistance,
n addition to the decrease in heart rate and cardiac output. Future
tudies will be necessary to clarify these possibilities.
In summary, the results obtained in the present study show that
HR treated with oral formulation of Ang-(1–7) in combination to
-blocker, atenolol, have an improvement of lipid metabolism with
 reduction of total plasma cholesterol, improvement of oral fat load
olerance and an increase in the lipolytic response. These results
[
[s 43 (2013) 155–159
suggest an important effect of Ang-(1–7) as a pharmacological tool
for treating lipid alteration in hypertensive patients.
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